Effects of TGF-β on podocyte growth and disease progression in proliferative podocytopathies

Kidney and Blood Pressure Research

Volumn 33, Issue 1, 2010, Pages 24-29

  Lee, Hyun Soon ^a   Song, Chi Young ^a  

^a Seoul National University   (South Korea)

Author keywords

Cellular FSGS; Collapsing FSGS; Crescentic glomerulonephritis; Podocyte TGF ; Ras ERK; Smads

Indexed keywords

TRANSFORMING GROWTH FACTOR ALPHA;

APOPTOSIS; CELL GROWTH; CELL PROLIFERATION; DISEASE COURSE; GENE OVEREXPRESSION; GLOMERULOPATHY; HUMAN; MESANGIUM CELL; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROLIFERATIVE PODOCYTOPATHY; SHORT SURVEY; SIGNAL TRANSDUCTION;

GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; PODOCYTES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950208651     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000285844     Document Type: Short Survey

References (65)

1. Appel D, Kershaw DB, Smeets B, Yuan G, Fuss A, Frye B, Elger M, Kriz W, Floege J, Moeller MJ: Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009; 20: 333-343.
2. Kriz W: Progressive renal failure - inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Nephrol Dial Transplant 1996; 11: 1738-1742.
3. Kriz W, Le Hir M: Pathways to nephron loss starting from glomerular diseases - insights from animal models. Kidney Int 2005; 67: 404-419.
4. Mundel P, Shankland SJ: Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13: 3005-3015.
5. Chun MJ, Kobert SM, Schwartz MM, Lewis EJ: Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15: 2169-2177.
6. Schwartz MM, Evans J, Bain R, Korbet SM: Focal segmental glomerulosclerosis: prognostic implications of the cellular lesions. J Am Soc Nephrol 1999; 10: 1900-1907.
7. Bariety J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A: Podocytes undergo phenotypic changes and express macrophagicassociated markers in idiopathic collapsing glomerulopathy. Kidney Int 1998; 53: 918-928.
8. Barisoni L, Kriz W, Mundel P, D'Agati V: The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10: 51-61.
9. Detwiler RK, Falk RJ, Hogan SL, Jennette JC: Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994; 45: 1416-1424.
10. Bariety J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacquot C: Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int 2005; 68: 1109-1119.
11. Ding M, Cui S, Li C, Jothy S, Haase V, Steer BM, Marsden PA, Pippin J, Shankland S, Rastaldi MP, Cohen CD, Kretzler M, Quaggin SE: Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med 2006; 12: 1081-1087.
12. Griffin S, Krofft RD, Pippin JW, Shankland SJ: Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis. Kidney Int 2005; 67: 977-986.
13. Moeller MJ, Soofi A, Hartmann I, Le Hir M, Wiggins R, Kriz W, Holzman LB: Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 2004; 15: 61-67.
14. Thorner PS, Ho M, Eremina V, Sado Y, Quaggin S: Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 2008; 19: 495-502.
15. Patek CE, Fleming S, Miles CG, Bellamy CO, Ladomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML: Murine Denys-Drash syndrome: evidence of podocyte dedifferentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet 2003; 12: 2379-2394.
16. Barisoni L, Nelson PJ: Collapsing glomerulopathy: an inflammatory podocytopathy? Curr Opin Nephrol Hypertens 2007; 16: 192-195.
17. Kopp JB, Factor VM, Mozes M, Nagy P, Sanderson N, Böttinger EP, Klotman PE, Thorgeirsson SS: Transgenic mice with increased plasma levels of TGF- 1 develop progressive renal disease. Lab Invest 1996; 74: 991-1003.
18. Sanderson N, Factor V, Nagy P, Kopp J, Kondalah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS: Hepatic expression of mature transforming growth factor 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 1995; 92: 2572-2576.
19. Shimizu M, Kondo S, Urushihara M, Takamatsu M, Kanemoto K, Nagata M, Kagami S: Role of integrin-linked kinase in epithelial mesenchymal transition in crescent formation of experimental glomerulonephritis. Nephrol Dial Transplant 2006; 21: 2380-2390.
20. Kim HW, Moon KC, Park SY, Hong HK, Lee HS: Differential expression of platelet-derived growth factor and transforming growth factor- in relation to progression of IgA nephropathy. Nephrology 2002; 7:S131-S139.
21. Kim JH, Kim BK, Moon KC, Hong HK, Lee HS: Activation of the TGF- Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 2003; 64: 1715-1721.
22. He JC, Husain M, Sunamoto M, D'Agati VD, Klotman ME, Iyengar R, Klotman PE: Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 2004; 114: 643-651.
23. Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385-1393.
24. Chan KT, Papeta N, Martino J, Zheng Z, Frankel RZ, Klotman PE, D'Agati VD, Lifton RP, Gharavi AG: Accelerated development of collapsing glomerulopathy in mice congenic for the HIVAN1 locus. Kidney Int 2009; 75: 366-372.
25. Bariety J, Bruneval P, Hill G, Irinopoulou T, Mandet C, Meyrier A: Posttransplantation relapse of FSGS is characterized by glomerular epithelial cell transdifferentiation. J Am Soc Nephrol 2001; 12: 261-274.
26. Stokes MB, Davis CL, Alpers CE: Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis 1999; 33: 658-666.
27. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC: Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004; 43: 368-382.
28. Barisoni L, Schnaper HW, Kopp JB: Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Arch Pathol Lab Med 2009; 133: 201-216.
29. Stokes MB, Valeri AM, Markowitz GS, D'Agati VD: Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney Int 2006; 70: 1783-1792.
30. Whitworth JA, Turner DR, Leibowitz S, Cameron JS: Focal segmental sclerosis or scarred focal proliferative glomerulonephritis? Clin Nephrol 1978; 9: 229-235.
31. Huppes W, Hene RJ, Kooiker CJ: The glomerular tip lesion: a distinct entity or not? J Pathol 1988; 154: 187-190.
32. Yamada S, Masutani K, Katafuchi R, Fujigaki Y, Muranaka Y, Tsuruya K, Iida M: Focal segmental glomerulosclerosis with intramembranous vesicle-like microstructures and podocytic infolding lesion. Clin Exp Nephrol 2008; 12: 509-512.
33. Arrizabalaga P, Sans Boix A, Torras Rabassa A, Darnell Tey A, Revert Torrellas L: Monoclonal antibody analysis of crescentic membranous glomerulonephritis. Am J Nephrol 1998; 18: 77-82.
34. Tse WY, Howie AJ, Adu D, Savage CO, Richards NT, Wheeler DC, Michael J: Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Nephrol Dial Transplant 1997; 12: 1017-1027.
35. Mazzucco G, Bertani T, Fortunato M, Bernardi M, Leutner M, Boldorini R, Monga G: Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis 2002; 39: 713-720.
36. Nasr SH, D'Agati VD, Said SM, Stokes MB, Appel GB, Valeri AM, Markowitz GS: Pauciimmune crescentic glomerulonephritis superimposed on diabetic glomerulosclerosis. Clin J Am Soc Nephrol 2008; 3: 1282-1288.
37. Lee HS, Song CY: Differential role of mesangial cells and podocytes in TGF- induced mesangial matrix synthesis in chronic glomerular disease. Histol Histopathol 2009; 24: 901-908.
38. Massague J, Blain SW, Lo RS: TGF- signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.
39. Ijichi H, Otsuka M, Tateishi K, Ikenoue T, Kawakami T, Kanai F, Arakawa Y, Seki N, Shimizu K, Miyazono K, Kawabe T, Omata M: Smad4-independent regulation of p21/ WAF1 by transforming growth factor. Oncogene 2004; 23: 1043-1051.
40. Liu S, Liang Y, Huang H, Wang L, Li Y, Li J, Li X, Wang H: ERK-dependent signaling pathway and transcriptional factor Ets-1 regulate matrix metalloproteinase-9 production in transforming growth factor- 1 stimulated glomerular podocytes. Cell Physiol Biochem 2005; 16: 207-216.
41. Schiffer M, Mundel P, Shaw AS, Böttinger EP: A novel role for the adaptor molecule CD2-associated protein in transforming growth factor- -induced apoptosis. J Biol Chem 2004; 279: 37004-37012.
42. Massague J, Wotton D: Transcriptional control by the TGF- Smad signaling system. EMBO J 2000; 19: 1745-1759.
43. Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A: Role of Smad proteins and transcription factor Sp1 in p21 Waf1/Cip1 regulation by transforming growth factor- - . J Biol Chem 2000; 275: 19244-19256.
44. Schiffer M, Bitzer M, Roberts ISD, Kopp JB, ten Dijke P, Mundel P, Böttinger EP: Apoptosis in podocytes induced by TGF and Smad7. J Clin Invest 2001; 108: 807-816.
45. Schiffer M, Schiffer LE, Gupta A, Shaw AS, Roberts ISD, Mundel P, Böttinger EP: Inhibitory Smads and TGF- signaling in glomerular cells. J Am Soc Nephrol 2002; 13: 2657-2666.
46. Hartsough MT, Frey RS, Zipfel PA, Buard A, Cook SJ, McCormick F, Mulder KM: Altered transforming growth factor- signaling in epithelial cells when ras activation is blocked. J Biol Chem 1996; 271: 22368-22375.
47. Kretzschmar M, Doody J, Timokhina I, Massague J: A mechanism of repression of TGF- - /Smad signaling by oncogenic Ras. Genes Dev 1999; 13: 804-816.
48. Kivinen L, Laiho M: Ras- and mitogen-activated protein kinase kinase-dependent and -independent pathways in p21 Cip1/Waf-1 induction by fibroblast growth factor-2, platelet- derived growth factor, and transforming growth factor-- 1 . Cell Growth Differ 1999; 10: 621-628.
49. Johnson GL, Lapadat R: Mitogen-activated kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298: 1911-1912.
50. Massague J, Chen YG: Controlling TGF- signaling. Genes Dev 2000; 14: 627-644.
51. Wada T, Pippin JW, Terada Y, Shankland SJ: The cyclin-dependent kinase inhibitor p21 is required for TGF- - 1 -induced podocyte apoptosis. Kidney Int 2005; 68: 1618-1629.
52. Davies CC, Mason J, Wakelam MJO, Young LS, Eliopoulos AG: Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004; 279: 1010-1019.
53. Lee EY, Chung CH, Khoury CC, Yeo TK, Pyagay PE, Wang A, Chen S: The monocyte chemoattractant protein-1/CCR2 loop, inducible by TGF- increases podocyte motility and albumin permeability. Am J Physiol Renal Physiol 2009; 297:F85-F94.
54. Masaki T, Stambe C, Hill PA, Dowling J, Atkins RC, Nikolic-Paterson DJ: Activation of the extracellular-signal regulated protein kinase pathway in human glomerulopathies. J Am Soc Nephrol 2004; 15: 1835-1843.
55. Song CY, Kim BC, Hong HK, Lee HS: TGF- type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis. Kidney Int 2007; 71: 882-888.
56. Ammit AI, Panettieri RA Jr: The circle of life: cell cycle regulation in airway smooth muscle. J Appl Physiol 2001; 91: 1431-1437.
57. Pettermann A, Hiromura K, Pippin J, Blonski M, Couser WG, Kopp J, Mundel P, Shankland SJ: Differential expression of D-type cyclins in podocytes in vitro and in vivo. Am J Pathol 2004; 164: 1417-1424.
58. Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, Mundel P: Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 2000; 58: 137-143.
59. Wang S, Kim JH, Moon KC, Hong HK, Lee HS: Cell cycle mechanisms involved in podocyte proliferation in cellular lesion of focal segmental glomerulosclerosis. Am J Kidney Dis 2004; 43: 19-27.
60. Korgaonkar SN, Feng X, Ross MD, Lu T-C, D'Agati V, Iyengar R, Klotman PE, He JC: HIV-1 upregulates VEGF in podocytes. J Am Soc Nephrol 2008; 19: 877-883.
61. Hellwig-Bürgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W: Hypoxia-inducible factor-1: a novel transcription factor in immune reactions. J Interferon Cytokine Res 2005; 25: 297-310.
62. Xavier S, Niranjan T, Krick S, Zhang T, Ju W, Shaw AS, Schiffer M, Böttinger EP: TR1 independently activates Smad- and CD2APdependent pathways in podocytes. J Am Soc Nephrol 2009; 20: 2127-2137.
63. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, Zanchi C, Longaretti L, Donadelli R, Remuzzi G: Transforming growth factor- 1 is upregulated by podocytes in response to excess intraglomerular passage of proteins. A central pathway in progressive glomerulosclerosis. Am J Pathol 2002; 161: 2179-2193.
64. Kwoh C, Shannon MB, Miner JH, Shaw A: Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol Mech Dis 2006; 1: 349-374.
65. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.